JOURNAL CLUB SUMMARIES

What’s hot that the other lot got

Candy Lee

NON-MALIGNANT PLEURAL EFFUSION
This UK prospective study (Walker et al. Chest 2017;151:1099–105) assessed the mortality risk and associated prognostic factors for patients with non-malignant pleural effusions (NMPE). A total of 782 patients were included, of whom 356 (46%) were diagnosed with NMPE. Effusions secondary to organ dysfunction were reported by the authors to have an ‘extremely high’ 1 year mortality. Pleural effusions secondary to cardiac, renal and hepatic failure had a reported 1 year mortality of 50%, 46% and 25%, respectively. The presence of bilateral effusions (HR 3.55; 95% CI 2.22 to 5.68) or a transudative effusion (HR 2.78; 95% CI 1.81 to 4.28) was found to be associated with a worse prognosis, with an increased 1 year mortality rate of 57% and 43%, respectively. NMPE is common and can cause significant morbidity and mortality. The authors conclude that clinicians should be aware of the poor prognostic features in NMPE and guide management accordingly.

MEPOLIZUMAB AND REFRACTORY EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS
In this phase 3, randomised, placebo controlled, double blind, multicentre study (Wechsler et al. N Engl J Med 2017;376:1921–32), mepolizumab, an anti-interleukin 5 monoclonal antibody, was shown to increase remission rates as well as reducing exacerbations in patients with refractory eosinophilic granulomatosis with polyangiitis (EGPA) when used as add-on therapy. Patients received monthly subcutaneous injections of either mepolizumab (300 mg) or placebo over a 1 year period in addition to continuation of existing corticosteroid treatment. Remission was achieved in 28% of patients for >24 weeks in the mepolizumab cohort versus 3% in the placebo group (OR 5.91; 95% CI 2.68 to 13.03). A higher proportion of mepolizumab treated patients were also reported to be in remission at week 36 and week 48 compared with placebo (32% vs 3%; OR 16.74; 95% CI 3.61 to 77.56). More patients receiving mepolizumab used average daily doses of corticosteroid <4 mg during weeks 48–52 versus placebo (44% vs 7%; OR 0.2; 95% CI 0.09 to 0.41). Although mepolizumab appears effective in the management of refractory EGPA, it was also noted that remission was not achieved in 47% of patients receiving the treatment.

ACUTE PULMONARY EMBOLISM AND EXERCISE LIMITATION
Persisting shortness of breath and reduced exercise tolerance can be common complaints in some patients who have had successfully treated pulmonary embolism (PE). The frequency and predictors of exercise limitation after PE was investigated in this multicentred Canadian study (Kahn et al. Chest 2017;151:1058–68). Patients who had major comorbidities or a previous history of PE were excluded. The primary outcome was per cent predicted peak oxygen uptake (VO\textsubscript{2} peak) <80% at 1 year cardiopulmonary exercise testing (CPET). Along with CPET at 1, 6 and 12 months, patients also underwent physiological tests, including pulmonary function test (PFTs), echocardiogram, 6 min walk distance (6MWD) and repeat imaging. Although mean peak oxygen uptake increased significantly between 1 and 12 months on CPET, 46.5% of patients still had per cent predicted VO\textsubscript{2} peak <80% at 1 year. Low peak VO\textsubscript{2} was associated with significantly lower scores in quality of life measurements and significantly reduced 6MWD at 1 year. There was no significant difference demonstrated in PFTs, echocardiogram measurements or clot burden in patients with or without demonstrated exercise limitation on CPET. Predictors of primary outcome included male sex, increased body mass index, smoking history, reduced per cent predicted VO\textsubscript{2} peak at 1 month and reduced 6MWD at 1 month. Given the findings of the study, the authors conclude that deconditioning occurring after PE may be the cause of the exercise limitation.

DOMICILIARY NON-INVASIVE VENTILATION AND COPD
The use of domiciliary non-invasive ventilation (NIV) in conjunction with home oxygen therapy was demonstrated to prolong the time to readmission or death in patients with chronic obstructive pulmonary disease (COPD) who had persistent hypercapnia (2–4 weeks post resolution of respiratory acidosis) after an acute exacerbation in this phase 3, multicentre, UK randomised control trial (Murphy et al. JAMA 2017 317:2177-86). Patients were randomised to home oxygen plus NIV or home oxygen only. Mean inspiratory positive airway pressure of 24 cm H\textsubscript{2}O, mean expiratory positive airway pressure of 4 cm H\textsubscript{2}O and a backup rate of 14 breaths/min were used for the NIV settings. Median time to readmission or death was 4.3 months in the cohort that had NIV in addition to home oxygen versus 1.4 months for the group that had oxygen alone (adjusted HR 0.49; 95% CI 0.31 to 0.77). In the group receiving home oxygen plus NIV, the 12 month risk of readmission or death was 63.4% compared with 80.4% in the group with home oxygen only, with an absolute risk reduction of 17%.

SOCIOECONOMIC STATUS AND ASTHMA OUTCOMES
Asthma outcomes were reported to be worse in low income groups (defined as a household income <$50 000/year), regardless of inhaled corticosteroid dose, treatment adherence, baseline asthma control, race, body mass index, second-hand smoke exposure or perceived stress, by the authors of this study (Cardet et al. J Allergy Clin Immunol. doi:10.1016/j.jaci.2017.04.036) Using data collected from a randomised controlled trial, the study found that patients with a lower income had a significantly higher rate of treatment failure (RR 1.6; 95% CI 1.1 to 2.3) and exacerbations (RR 1.9; 95% CI 1.1 to 3.3), even after adjusting for multiple confounders. Although income was reported as an independent risk factor for worse asthma outcome, the study did not show a cause and effect relationship between income and asthma treatment failure.

Correspondence to Dr Candy Lee, Respiratory Medicine and General Internal Medicine, Abertawe Bro Morgannwg University Health Board, Princess of Wales Hospital, Colby Road, Bridgend, CF31 1LD, UK; clee12@doctors.org.uk

Lee C. Thorax August 2017 Vol 72 No 8

769